Compare TG Therapeutics Inc (TGTX) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Zoom Video Communications, Inc. — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Zoom Video Communications, Inc. trades at $89.57 (market cap $26.66B). The key difference: Zoom Video Communications, Inc. is far larger — about 3.2× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Zoom Video Communications, Inc. nearer its low. Which is the better fit depends on your goals.
| TGTX | ZM | |
|---|---|---|
Market Cap | $8.26B | $26.66B |
Sector | Health | Technology |
52-Week High | $59.06 | $111.88 |
52-Week Low | $26.39 | $69.77 |
Enterprise Value | $8.50B | $19.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoom Communications (ZM) trades at $89.77, down 1.49% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 77.4% gross margins and 42% net income margins, while recent AI-focused acquisitions and APAC leadership appointments signal growth initiatives. Q1 2026 earnings beat expectations with $1.55 EPS versus $1.42 expected.
Investment outlook remains positive with a $118.79 consensus price target offering 32% upside potential, though risks include competitive pressure from Microsoft and Google, insider selling activity, and fluctuating cash flow trends. Wall Street sentiment is mixed with 39% buy ratings versus 55% hold recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
